American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

New 4-Drug Combo Leads to Promising Responses in Multiple Myeloma

ASH 2019 – Multiple Myeloma: Wrap-Up

Patients with “challenging-to-treat” relapsed multiple myeloma showed promising responses to a new 4-drug combination, one of the first of its kind to be used in multiple myeloma. Read More ›

Characteristics of Patients with Mantle-Cell Lymphoma and Chronic Lymphocytic Leukemia Treated with Acalabrutinib in a US Real-World Setting

ASH 2019 – Wrap-up

Insights about real-world clinical experience with new drugs, such as acalabrutinib, are highly valuable. At ASH 2019, researchers evaluated acalabrutinib use in real-world patients with mantle-cell lymphoma and chronic lymphocytic leukemia. Read More ›

Venetoclax plus Ibrutinib in Mantle-Cell Lymphoma: 3-Year Study Update

ASH 2019 – CLL

Mantle-cell lymphoma is a relatively aggressive type of non-Hodgkin lymphoma. Results from a study of patients who elected to interrupt treatment with ibrutinib plus venetoclax are presented. Read More ›

Venetoclax and Ibrutinib for Relapsed and Refractory CLL: Interim Analysis of MRD Testing

ASH 2019 – CLL

Targeted drug treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are given indefinitely: either until disease progression or until side effects are no longer manageable. A key question is whether oncologists can use results of minimal residual disease (MRD) testing to determine if patients can take a break from treatment with targeted drugs. Read More ›

Acalabrutinib for Relapsed and Refractory CLL and SLL

ASH 2019 – CLL

Updated analysis of ASCEND trial showed that acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, improves progression-free survival compared with other treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Read More ›

A New Treatment Option for Relapsed/Refractory Multiple Myeloma

ASH 2019 – Multiple Myeloma: Wrap-Up

Now that patients with multiple myeloma are living longer, researchers are focusing more on patients’ quality of life during and after cancer treatment. New research says there’s good news: 1 study found that adding an extra drug to a standard treatment made patients live longer, with no negative impact on their quality of life. Read More ›

Phase 3 Trial Compares Acalabrutinib plus Venetoclax with or without Obinutuzumab versus Chemoimmunotherapy as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia and No del(17p) or TP53 Mutations

ASH 2019 – Wrap-up

Current treatments for chronic lymphocytic leukemia are limited by cost, toxicity, and duration of response. In the future, less toxic first-line chemotherapy-free regimens administered for a fixed duration of time may improve outcomes. Read More ›

The iR² Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ASH 2019 – CLL

Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant. Read More ›

Triple-Drug Combination for Relapsed and Refractory CLL

ASH 2019 – CLL

A study evaluating the safety and efficacy of a new 3-drug combination is underway in patients with relapsed and refractory chronic lymphocytic leukemia (CLL). Read More ›

Ibrutinib Combined with Venetoclax for First-Line Treatment of CLL and SLL

ASH 2019 – CLL

Results from a study of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to see if treatment with ibrutinib plus venetoclax could be stopped for those who have a good response. Read More ›

American Society of Hematology (ASH)

Page 15 of 44